50 / 78
144
Ces Urol 2015; 19(2): 137–144
ORIGINÁLNÍ PRÁCE
12. Weinberg RA.
The biology of cancer. 2. ed. New York: Garlan Science, Taylor & Francis Group, LLC 2014;
641–722.
13. Pal SK, He M, Wilson T, Liu X, Zhang K, et al.
Detection and phenotyping of cirulating tumor cells
in high-risk localized prostate cancer. Clin Genitourin Cancer 2014; doi: 10.1016/j.clgc.2014.08.014. V tisku.
14. Boorjian SA, Thompson RH, Siddiqui S, et al.
Long-term outcome after radical prostatectomy for
patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178:
864–870.
15. Heidenreich A, Bastian PJ, Bellmunt J, et al.
EAU guidelines on prostate cancer. part 1: screening,
diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65(1): 124–137.
16. Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE.
Survival in surgically treated,
nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary
tumor and its lymph node metastases. Prostate 2009; 69(4): 352–162.
17. Cheng L, Zincke H, Blute ML, et al.
Risk of prostate carcinoma death in patients with lymph node
metastasis. Cancer. 2001; 91(1): 66–73.
Využijte nového
redakčního systému ACTAVIA
pro zasílání Vašich rukopisů k publikaci